<DOC>
	<DOC>NCT02797015</DOC>
	<brief_summary>The purpose of this study is to learn about the pharmacokinetics and pharmacodynamics of RPC1063 in RMS.</brief_summary>
	<brief_title>Pharmacokinetics and Pharmacodynamics Study of RPC1063 in RMS</brief_title>
	<detailed_description>The purpose of this study is to characterize the full pharmacokinetic and pharmacodynamics profiles of RPC1063 in patients with relapsing multiple sclerosis (RMS) following multiple-dose administration of the two different dosing regimens that are being evaluated in the Phase 3 RMS studies.</detailed_description>
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<criteria>Key MS, as diagnosed by the revised 2010 McDonald criteria Exhibits a relapsing clinical course consistent with RMS and history of brain MRI lesions consistent with MS Expanded disability status scale (EDSS) score between 0 and 6.0 Key Primary progressive MS Clinically relevant cardiovascular conditions or other relevant diseases that could impact the implementation or interpretation of the trial, or put the patient at risk</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>MS</keyword>
	<keyword>RMS</keyword>
	<keyword>Multiple Sclerosis</keyword>
	<keyword>Relapsing Multiple Sclerosis</keyword>
</DOC>